| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
An orally active Amazonian plant extract (BIRM) inhibits prostate cancer growth and metastasis
|
Dandekar, Devendra S.
|
|
2003
|
52 |
1 |
p. 59-66
|
artikel
|
| 2 |
Anticancer drug development at the US National Cancer Institute
|
Takimoto, Chris H.
|
|
2003
|
52 |
1 |
p. 29-33
|
artikel
|
| 3 |
A population model of epirubicin pharmacokinetics and application to dosage guidelines
|
Ralph, Lorraine D.
|
|
2003
|
52 |
1 |
p. 34-40
|
artikel
|
| 4 |
Arsenic trioxide induces apoptosis in cells of MOLT-4 and its daunorubicin-resistant cell line via depletion of intracellular glutathione, disruption of mitochondrial membrane potential and activation of caspase-3
|
Hu, Xiao-Mei
|
|
2003
|
52 |
1 |
p. 47-58
|
artikel
|
| 5 |
Clinical effects of combination therapy with mitoxantrone, vincristine, and prednisolone in breast cancer
|
Katsumata, Kenji
|
|
2003
|
52 |
1 |
p. 86-88
|
artikel
|
| 6 |
Clinical significance of the expression of estrogen receptors α and β for endocrine therapy of breast cancer
|
Iwase, Hirotaka
|
|
2003
|
52 |
1 |
p. 34-38
|
artikel
|
| 7 |
Combination second-line chemotherapy with gemcitabine and docetaxel for recurrent non-small-cell lung cancer after platinum-containing chemotherapy: a phase I/II trial
|
Niho, Seiji
|
|
2003
|
52 |
1 |
p. 19-24
|
artikel
|
| 8 |
Combined effects of temozolomide and the ribonucleotide reductase inhibitors didox and trimidox in malignant brain tumor cells
|
Figul, M.
|
|
2003
|
52 |
1 |
p. 41-46
|
artikel
|
| 9 |
Monoclonal antibodies for the treatment of hematologic malignancies: clinical trials in Japan
|
Tobinai, Kensei
|
|
2003
|
52 |
1 |
p. 90-96
|
artikel
|
| 10 |
New approaches to drug discovery and development: a mechanism-based approach to pharmaceutical research and its application to BNP7787, a novel chemoprotective agent
|
Hausheer, Frederick H.
|
|
2003
|
52 |
1 |
p. 3-15
|
artikel
|
| 11 |
New approaches to the endocrine prevention and treatment of breast cancer
|
Howell, Anthony
|
|
2003
|
52 |
1 |
p. 39-44
|
artikel
|
| 12 |
Novel direct and indirect cyclin-dependent kinase modulators for the prevention and treatment of human neoplasms
|
Senderowicz, Adrian M.
|
|
2003
|
52 |
1 |
p. 61-73
|
artikel
|
| 13 |
Panel of human cancer cell lines provides valuable database for drug discovery and bioinformatics
|
Yamori, Takao
|
|
2003
|
52 |
1 |
p. 74-79
|
artikel
|
| 14 |
Pharmacogenomic applications in clinical drug development
|
Dracopoli, Nicholas C.
|
|
2003
|
52 |
1 |
p. 57-60
|
artikel
|
| 15 |
Pharmacokinetic and pharmacodynamic effects of oral eniluracil, fluorouracil and leucovorin given on a weekly schedule
|
Guo, Xiao-Du
|
|
2003
|
52 |
1 |
p. 79-85
|
artikel
|
| 16 |
Pharmacokinetics and tissue distribution of cryptophycin 52 (C-52) epoxide and cryptophycin 55 (C-55) chlorohydrin in mice with subcutaneous tumors
|
Boinpally, Ramesh R.
|
|
2003
|
52 |
1 |
p. 25-33
|
artikel
|
| 17 |
Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors
|
Peters, G. J.
|
|
2003
|
52 |
1 |
p. 1-12
|
artikel
|
| 18 |
Phase I and pharmacokinetic study of carboplatin and paclitaxel with a biweekly schedule in patients with advanced non-small-cell lung cancer
|
Ichiki, M.
|
|
2003
|
52 |
1 |
p. 67-72
|
artikel
|
| 19 |
Phase I/II study of escalating doses of nedaplatin in combination with irinotecan for advanced non-small-cell lung cancer
|
Oshita, Fumihiro
|
|
2003
|
52 |
1 |
p. 73-78
|
artikel
|
| 20 |
Preface
|
|
|
2003
|
52 |
1 |
p. 1-2
|
artikel
|
| 21 |
Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: a randomized trial
|
Santoso, Joseph T.
|
|
2003
|
52 |
1 |
p. 13-18
|
artikel
|
| 22 |
Strategy for the development of novel anticancer drugs
|
Saijo, Nagahiro
|
|
2003
|
52 |
1 |
p. 97-101
|
artikel
|
| 23 |
Structural development of synthetic retinoids and thalidomide-related molecules
|
Hashimoto, Yuichi
|
|
2003
|
52 |
1 |
p. 16-23
|
artikel
|
| 24 |
Survival-signaling pathway as a promising target for cancer chemotherapy
|
Fujita, Naoya
|
|
2003
|
52 |
1 |
p. 24-28
|
artikel
|
| 25 |
The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones
|
Workman, Paul
|
|
2003
|
52 |
1 |
p. 45-56
|
artikel
|
| 26 |
Thymidylate synthase inhibitors as anticancer agents: from bench to bedside
|
Chu, Edward
|
|
2003
|
52 |
1 |
p. 80-89
|
artikel
|
Tijdschrift beschrijving